Remedium Bio, Inc. announces research agreement to evaluate platform technology in Diabetes with the University of Massachusetts Boston
BOSTON, Jan. 10, 2022 /PRNewswire/ -- Remedium Bio, Inc., a biotechnology company developing novel gene therapies, is pleased to announce it has entered into a Sponsored Research Agreement with the University of Massachusetts Boston to complete pre-clinical efficacy studies on Type 1 and Type 2 Diabetes pipeline candidates. The collaboration will evaluate platform technology for the treatment of Diabetes, with translational potential to the broader Remedium pipeline of single-injection potentially disease-modifying gene therapies.
The initiation of this research program is a transformational milestone for Remedium.
The research is being led by Dr. Kai Zou, PhD, Assistant Professor at the Department of Exercise and Health Sciences under the Robert and Donna Manning College of Nursing and Health Sciences at the University of Massachusetts Boston. Dr. Zou's laboratory has expertise in characterizing metabolic dysfunction associated with Diabetes and has extensive know-how in the fields of endocrine dysregulation, insulin resistance, impaired glucose metabolism, and associated molecular pathophysiological mechanisms. Dr. Zou has extensive expertise in endocrinology having generated high-impact publications in journals including the Journal of Physiology, Surgery, Physiological Genomics, and International Journal of Obesity.
"The initiation of this research program is a transformational milestone for Remedium" said Frank Luppino, CEO of Remedium Bio. "Through this partnership, Remedium will expand its development portfolio and validate our gene-therapy dose-adjustment platform, which has broad therapeutic applicability beyond the currently targeted indications".
To learn more, visit www.remedium-bio.com.
About UMass Boston
To learn more, visit www.umb.edu.
Contact Remedium: email@example.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/remedium-bio-inc-announces-research-agreement-to-evaluate-platform-technology-in-diabetes-with-the-university-of-massachusetts-boston-301453828.html
SOURCE Remedium Bio, Inc.